Dear Dr. Müller and colleagues:

Thank you for your letter raising your concerns about the unique genetic, surgical, environmental, and lifestyle factors affecting the vascular biology of patients with congenital heart disease.

Our review was focused more on the effects of COVID-19 on the cardiovascular system and how it applies to patients with congenital heart disease, and not necessarily on the effect that congenital heart disease has on the lifelong vascular health of these patients.

We agree that there is still a lot to be understood about the role of surgical procedures, artificial material used in conduits and patches, and inflammatory processes like cardiopulmonary bypass on the development and long-term outcome of the arterial and venous anatomy of patients with congenital heart disease. Further research is also required to identify which genetic factors and other immunomodulatory pathways affect the endothelial function and arterial stiffness in patients with congenital heart disease.

With respect to COVID-19, recent research has highlighted the role of microthrombi formation \[[@bb0005]\] and endothelitis \[[@bb0010]\] caused by direct invasion of virus particles in the pathogenesis of COVID-19. The point that you and your colleagues made is a good one -- patients with congenital heart disease have a unique set of genetic, biologic, and anatomic characteristics that make them possibly more vulnerable to COVID-19 and other diseases in general, and it will take a strong group effort to tackle this problem.

Respectfully,

Weiyi Tan, MD, and Jamil Aboulhosn, MD
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